Navigation Links
Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Date:5/30/2009

Data Presented at 45th American Society of Clinical Oncology Annual Meeting

Abstracts: 5033, 3560

ORLANDO, Fla., May 30 /PRNewswire/ -- Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Bayer is committed to discovering new cancer-fighting therapies," said Kemal Malik, MD, Chief Medical Officer and Head of Global Development at Bayer HealthCare. "We are encouraged by these Phase I and II data being presented on BAY 73-4506. These data will help further determine our next steps as we move forward with a comprehensive Phase III clinical development program in various tumor types for this new drug candidate."

Preliminary data from the Phase II, open-label study in renal cell carcinoma (RCC) demonstrated a 27 percent partial response (PR) rate according to the Response Evaluation Criteria in Solid Tumors (RECIST) and a disease control rate of 79 percent. The most common drug-related adverse events were hand-foot skin reaction (HFSR), fatigue, hypertension, mucositis, dysphonia, rash, diarrhea, and anorexia. The Phase II study enrolled 49 previously untreated patients with predominantly clear cell RCC. BAY 73-4506 (160 mg) was administered once daily on a three weeks on/one week off schedule. The primary endpoint was to evaluate response rate according to RECIST.

"We are encouraged by these data of BAY 73-4506," said lead investigator Professor Tim Eisen, F.R.C.P., PhD, of Addenbrooke's Hospital at the University of Cambridge, UK. "These data provide a rationale to move into a Phase III trial in one of the multiple tumor types that may be responsive to BAY 73-4506."

Additional data presented on BAY 73-4506 include a Phase I study
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Aileron Therapeutics, ... Summary Global Markets Direct,s, ,Aileron Therapeutics, Inc. ... overview of the Aileron Therapeutics, Inc.,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... various stages, therapeutics assessment by drug target, mechanism ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... 2014   Easy Breathe , the fastest growing ... that it now offers the revolutionary AirSense ... first sleep apnea therapy devices with internal cellular modems.  ... track and share real-time data on each user,s quality ... therapy.  In addition, the internal modem allows the CPAP ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... BEDFORD, Mass., Feb. 4, 2011 Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... products dedicated to serving the healthcare needs of ... Administration (FDA) has approved Hologic,s pharmaceutical named Makena™ ...
... SPRING, Md., Feb. 4, 2011 The U.S. Food ... to reduce the risk of preterm delivery before 37 ... of at least one spontaneous preterm birth.   ... is not intended for use in women with a ...
Cached Medicine Technology:FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women 2FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women 3
(Date:10/1/2014)... 2014 The Oliver Law Group ... Other-Sonic Ultrasound Gel lawsuit web page ... litigation surrounding the 2011 Pseudomonas aeruginosa / bacterial ... Oak, Michigan, which was ultimately traced to the ... William Beaumont patients who allegedly became ill following ...
(Date:10/1/2014)... The annual Social Security cost-of-living adjustment (COLA) ... a new forecast by The Senior Citizens League (TSCL) ... (CPI) data through August, TSCL forecasts that COLAs will be ... consecutive year of record low COLAs,” states TSCL Chairman, Ed ... in 1975,” he notes. , Over the past five years ...
(Date:9/30/2014)... same time could stop them from becoming resistant to ... Research * today (Wednesday). , The researchers, ... MedImmune, the global biologics research and development arm of ... two treatments helped the immune system hunt down and ... radiotherapy in mice with breast, skin and bowel cancers. ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... surfaced in the United States, involving a man who recently ... The critically ill patient, being cared for at Texas ... the deadly virus, officials from the U.S. Centers for Disease ... The man is receiving intensive care in isolation at ...
(Date:9/30/2014)... for doctors to measure damaging "brain tsunamis" in ... a step closer to reality, thanks to pioneering ... Institute. , The research team, led by Jed ... of neurosurgery at the UC College of Medicine, ... through an injured brain like tsunami wavescan be ...
Breaking Medicine News(10 mins):Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3Health News:Immunotherapy could stop resistance to radiotherapy 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3
... skateboarders have better self-esteem and lower tendencies to engage ... // ,The report of the study will ... authored by Melissa Nelson, professor and epidemiologist at the ... assistant professor of nutrition at the University of North ...
... being failed by the NHS says a joint report from ... Social Care Inspection. // Elder abuse is hurting old people, ... subject to patronising and thoughtless attitudes from some doctors and ... another, their meals are whisked away uneaten for lack of ...
... they had accomplished the transformation of immature cells from ... differentiate into nerve, heart and bone cells. // Their ... researchers in Valencia, Spain. Gerd Hasenfuss of Georg-August-University in ... that they have transformed mouse germ cells into stem ...
... of hundreds of birds in Peshawar and adjacent areas ... of blood samples to the National Veterinary Research Laboratory, ... that no case of bird flu was detected in ... had scared the people of the area following confirmation ...
... outbreak of measles occurred among the kids which were later ... the Central Middlesex Hospital in north-west London// began after two ... hundreds of hospital staffs are being vaccinated against measles. The ... the hospital scenario. ,Six nurses contracted the disease ...
... NHS of more than ?600,000 has been sentenced to three ... carried on// this fraud for more than six years during ... payment. ,The Hull Crown Court was told that ... work, which was never done. The dentist has earlier pleaded ...
Cached Medicine News:Health News:Neglect of the Elderly by the Community 2Health News:Bird Flu Not The Cause For Mysterious Bird Deaths 2
... Quieter Compressed Air., ,Allied Healthcares Timeter® PCS ... than other air compressors that you may wonder ... The PCS 414 features a durable, mar-resistant steel ... the unit weighs only 26.5 pounds. The PCS ...
... most compact, portable DC powered compressor ... provides the freedom to take nebulizer ... is powered by the included AC ... and Battery Kit. The integral reusable ...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
... Compressor provides effective therapy at an affordable price. ... home or on the go and features ease ... reliable operation you have come to count on ... the perfect solution for those patients seeking a ...
Medicine Products: